Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
ARDX Stock Chart & Stats
$6.27
-$0.17(-3.14%)
At close: 4:00 PM EST
$6.27
-$0.17(-3.14%)
Day’s Range― - ―
52-Week Range$3.21 - $8.40
Previous CloseN/A
Volume1.36M
Average Volume (3M)3.90M
Market Cap
$1.54B
Enterprise Value$1.66B
Total Cash (Recent Filing)$264.69M
Total Debt (Recent Filing)$211.59M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Apr 30, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding245,247,420
10 Day Avg. Volume5,737,255
30 Day Avg. Volume3,900,231
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)8.42
Price to Sales (P/S)3.45
P/FCF Ratio-31.96
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue4.08
Enterprise Value/Gross Profit4.52
Enterprise Value/Ebitda-56.96
Forecast
1Y Price Target
$16.38Price Target Upside161.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.19
Revenue Forecast (FY)$542.64M
Bulls Say, Bears Say
Bulls Say
Commercial ExecutionExpansion of the commercial team together with patient assistance programs and field access managers has improved physician reach and prescription pull-through, supporting stronger sales momentum for Ibsrela and Xphozah.
Intellectual PropertyA newly allowed formulation and manufacturing patent listed in the Orange Book could extend exclusivity for Ibsrela and Xphozah, strengthening long-term revenue visibility and deterring generic competition.
Label ExpansionInitiation of a late-stage clinical trial to evaluate Ibsrela in chronic idiopathic constipation opens the possibility of expanding approved use to a substantially larger patient population, increasing the drug's addressable market.
Bears Say
Adoption RiskKey uncertainty about whether growth initiatives will drive sufficient prescriber adoption creates execution risk that could temper revenue growth versus expectations.
Medicare Coverage HeadwindsManagement's expectation that Xphozah will not be re-included in Medicare Part D may constrain uptake among Medicare patients and limit revenue potential for that product.
Near-term Revenue MomentumGuidance indicating modest near-term revenue trends for Xphozah suggests limited acceleration in sales, which could keep stock momentum constrained.
Ardelyx News
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $3.21 and its highest was $8.40 in the past 12 months.
What is Ardelyx’s market cap?
Ardelyx’s market cap is $1.54B.
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Apr 30, 2026 which is in 54 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Feb 19, 2026. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.013 by -$0.013.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is -0.12.
How many shares outstanding does Ardelyx have?
Ardelyx has 245,247,420 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of $0 in its last earnings report, missing expectations of $0.013. Following the earnings report the stock price went down -14.985%.
Which hedge fund is a major shareholder of Ardelyx?
Currently, no hedge funds are holding shares in ARDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ardelyx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.38 (161.24% Upside)
$16.38 (161.24% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 350.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.25%
12-Months-Change
Fundamentals
Return on Equity
-36.21%
Trailing 12-Months
Asset Growth
15.39%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
ARDX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum driven by IBSRELA (73% revenue growth in 2025), meaningful revenue guidance and a strengthened pipeline (Phase III CIC trial and next-gen NHE3), supported by improved cash and a new Orange Book-listed formulation patent. Counterbalancing that are a sizable decline in XPHOZAH revenue due to Medicare reimbursement changes, materially higher SG&A/R&D spending and a wider net loss. Management is investing to scale IBSRELA and advance pipeline programs and expects these investments to drive outsized revenue growth versus expense growth over time.View all ARDX earnings summariesARDX Stock 12 Month Forecast
Average Price Target
$16.38
▲(161.24% Upside)
Technical Analysis
Vericel
―
Viridian Therapeutics
―
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Ownership Overview
3.68% Insiders
23.40% Mutual Funds
1.49% Other Institutional Investors
57.91% Public Companies and
Individual Investors